US 11,318,158 B2 · Pappalysin regulator

Abstract

A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.

Claims11

Dependent claims

An assay for screening if an agent is capable of antagonizing complex formation between a stanniocalcin and a Pappalysin comprising the steps of:

(a) providing a Pappalysin polypeptide and a stanniocalcin polypeptide, wherein the Pappalysin is PAPP-A (SEQ ID NO:3) or PAPP-A2 (SEQ ID NO:4) and wherein the stanniocalcin is STC1 (SEQ ID NO:
1) or STC2 (SEQ ID NO:2),
(b) providing said agent,
(c) incubating said agent with said Pappalysin and stanniocalcin,
(d) detecting the presence or absence of interacting Pappalysin and stanniocalcin, and
(e) on the basis of the presence or absence of interacting Pappalysin and stanniocalcin in step d, determining whether said agent is capable of antagonizing complex formation between Pappalysin and stanniocalcin.

3 more elements

Dependencies are inferred from the claim text.

Pappalysin regulator

Life of this patent

Pappalysin regulator

Life of this patent

Abstract

Claims11